By Aaron Nicodemus2023-03-14T20:22:00
A New York-based investment adviser will pay a $50,000 fine and be required to hire an independent compliance consultant for allegedly failing to implement compliance policies and procedures following the death of its founder and chief compliance officer.
E. Magnus Oppenheim & Co. (EMO) also failed to conduct best execution reviews for its advisory clients from 2019-21, the Securities and Exchange Commission (SEC) alleged Monday in its order. In settling, the firm agreed to be censured and cease and desist from future violations.
In June 2019, the firm’s namesake and founder died. E. Magnus Oppenheim had served as president, chief investment officer, and CCO.
2023-06-16T17:51:00Z By Kyle Brasseur
Pacific Investment Management Company agreed to pay a combined $9 million to resolve two separate actions brought by the Securities and Exchange Commission regarding alleged violations of the Advisers Act.
2023-03-23T15:22:00Z By Aaron Nicodemus
What is compliance resiliency, and why is it crucial for your organization to have it? Recent enforcement examples demonstrate why mapping out a clear business continuity plan can help thwart a risky management reshuffle.
2022-12-08T16:05:00Z By Aaron Nicodemus
Two Point Capital Management and its CEO John McGowan were fined a total of $100,000 by the Securities and Exchange Commission for failing to adopt and implement policies and procedures tailored to guide the firm’s compliance with federal securities law.
2025-08-06T20:18:00Z By Aly McDevitt
A delayed product hazard report cost one company criminal and civil penalties—and a mother her life. This case shows why timely reporting and executive accountability are non-negotiable for compliance teams.
2025-08-06T14:00:00Z By Oscar Gonzalez
The Trump administration declawed the Consumer Financial Protection Bureau from the very beginning of his second term. It now appears the agency might be running out of money.
2025-08-05T16:23:00Z By Adrianne Appel
The Securities and Exchange Commission and Department of Justice ended a seven-year review of GE HealthCare Technologies’ China unit for possible violations of the Foreign Corrupt Practices Act.
Site powered by Webvision Cloud